Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

Br J Haematol. 2013 Aug;162(4):548-52. doi: 10.1111/bjh.12382. Epub 2013 May 21.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Imidazoles / therapeutic use*
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridazines / therapeutic use*
  • Recurrence
  • Remission Induction
  • Salvage Therapy
  • Tandem Repeat Sequences
  • fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Imidazoles
  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Pyridazines
  • ponatinib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3